Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›Flexbumin 200 g/l solution for infusion
Medicines register · Ireland

Flexbumin 200 g/l solution for infusion

Authorisation PA2004/002/001 · Baxalta Innovations GmbH

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 22 Nov 2026
Licence holder
Baxalta Innovations GmbH (all products →)
Active substance
Human plasma protein
Dosage form
Solution for infusion
Route of administration
Intravenous use
ATC codes
B05AA, B05AA01
First authorised
24/08/2007
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Well-established use application (Article 10a of Directive No 2001/83/EC)

Human plasma protein: supply and approvals

6 authorised products on the HPRA list contain Human plasma protein. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 21 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 21 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 21 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 19 years (since 24 August 2007). The HPRA list marks it as marketed in Ireland.

Other medicines with Human plasma protein in Ireland

5 other products on the HPRA list contain Human plasma protein, from 3 licence holders; 4 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
Hepatect CP 50 IU/ml solution for infusionBiotest Pharma GmbHNational authorisation (PA)Marketed
Intratect 100 g/L, solution for infusionBiotest Pharma GmbHNational authorisation (PA)Marketed
LG-octaplas, solution for infusionOctapharma (IP)National authorisation (PA)Marketed
Tetagam P, prefilled syringeSolution for injection for intramuscular useCSL Behring GmbHNational authorisation (PA)Marketed
LG-octaplas, Powder and solvent for solution for infusionOctapharma (IP)National authorisation (PA)Not stated

Other substances in ATC group B05AA

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 14 other active substances share the group B05AA with this product:

Sodium chloride (4) · Potassium chloride (3) · Magnesium chloride hexahydrate (3) · Human plasma protein not containing less than 96% human albumin (2) · Human albumin (2) · Succinylated gelatine (= modified fluid gelatine) (2) · Modified liquid gelatine (2) · Plasma protein containing at least 95% human albumin (2) · Sodium acetate trihydrate (1) · Calcium chloride dihydrate (1) · Sodium hydroxide (1) · Sodium (s)-lactate solution (1) · Sodium lactate solution (1) · Human albumin macro aggregated (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Baxalta Innovations GmbH holds 21 products on the HPRA list, with 14 different active substances; 5 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.